title: CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL).
abstract: Immunophenotyping disclosed CD10 negativity in 70 of 2408 cases of B-lineage acute lymphoblastic leukemia (ALL), although other criteria followed classification of pre-B ALL (eg, cytoplasmic immunoglobulin positivity). These blasts showed high myeloid antigen expression (60% CD65 positivity) and reacted with antibody 7.1 in 95% of the cases. MLL-AF4 fusion transcripts or an 11q23/MLL rearrangement or both were evident in 46 of 56 samples (82%). Although 83% of the patients achieved complete remission, the remission duration remained remarkably low: 141 days for MLL rearrangement-positive and 245 days for MLL rearrangement-negative CD10(-) pre-B ALL. Thus, the overall survival probability 3 years after diagnosis was 0.34 +/- 0.20 SE in MLL-rearrangement-negative versus 0.12 +/- 0.06 SE in MLL rearrangement-positive CD10- pre-B ALL. Our data identify CD10- cytoplasmic immunoglobulin-positive pre-B ALL as a rare (2.2%) but distinct immuno-subtype of adult ALL that is characterized by a high MLL rearrangement rate and a worse outcome.
authors.affiliation: Department of Internal Medicine III, Campus Benjamin Franklin, Charité Universitätsmedizin, Hindenburgdamm 30, 12200 Berlin, Germany. beate.gleissner@charite.de
authors.forename: Beate
authors.initials: B
authors.lastname: Gleissner
authors.forename: Nicola
authors.initials: N
authors.lastname: Goekbuget
authors.forename: Harald
authors.initials: H
authors.lastname: Rieder
authors.forename: Renate
authors.initials: R
authors.lastname: Arnold
authors.forename: Stefan
authors.initials: S
authors.lastname: Schwartz
authors.forename: Helmut
authors.initials: H
authors.lastname: Diedrich
authors.forename: Claudia
authors.initials: C
authors.lastname: Schoch
authors.forename: Barbara
authors.initials: B
authors.lastname: Heinze
authors.forename: Christa
authors.initials: C
authors.lastname: Fonatsch
authors.forename: Claus R
authors.initials: CR
authors.lastname: Bartram
authors.forename: Dieter
authors.initials: D
authors.lastname: Hoelzer
authors.forename: Eckhard
authors.initials: E
authors.lastname: Thiel
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002869:Chromosome Aberrations; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000378:metabolism*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D012307:Risk Factors; D015996:Survival Rate; D014158:Transcription, Genetic / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D015260:Neprilysin